OKYO Pharma Ltd. Form 6-K Summary
Business context and reporting period
OKYO Pharma Ltd. filed a Form 6-K on September 8, 2022, as a foreign private issuer reporting under Form 20-F. The filing furnishes a U.K. news service announcement regarding an interview scheduled to air on Bloomberg U.S. on the RedChip Money Report.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, operating, or other financial metrics.
Material changes versus the prior comparable period
No financial or operating changes versus a prior comparable period are disclosed.
Guidance, outlook, risks, and unusual items
The filing contains no earnings guidance, formal outlook, risk update, contingency, or unusual financial item. Exhibit 99.1 is furnished rather than filed and is not incorporated by reference into other filings except where expressly stated.
Important facts to verify
- Verify the content, timing, and scope of the Bloomberg U.S. interview referenced in Exhibit 99.1.
- Review Exhibit 99.1 for any management statements or forward-looking commentary not reproduced in the filing text.
- Do not treat this Form 6-K as providing updated financial results or liquidity information; those details are not included.